← Eichor
Study identifier: NCT03304314 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Multifocal Chromatic Pupilloperimetry in Patients With Pseudotumor Cerebri and Healthy Subjects.

Condition: Pseudotumor Cerebri  ·  Sponsor: Sheba Medical Center

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersYes

About this study

PTC(Pseudotumor cerebri) patients may develop increased Intracranial pressure (ICP) that can produces increased pressure around the distal optic nerve,which is likely followed by venule compression, ischemia, and loss of visual function.Vision loss in PTC is most commonly characterized by standard automated perimetry to measure peripheral visual field sensitivity. Pupillometry is a promising approach for functional assessment in PTC because it is noninvasive, objective, performed quickly with minimal patient cooperation needed. The feasibility of using chromatic multifocal pupillometry for assesment of PTC will be examined.

This description comes directly from the study's public registry record.

Talk to the study team

Ygal Rotenstreich, MD  ·  972-35302880  ·  ygal.rotenstreich@sheba.health.gov.il

Ifat Sher, PhD  ·  ifat.sherrosenthal@sheba.health.gov.il

Always discuss trial participation with your own doctor first.

Locations (1)

Sheba Medical CenterTel Litwinsky, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03304314